New Findings on COVID-19 Vaccination in Pregnancy and Preeclampsia

A recent analysis by the INTERCOVID Consortium observed lower reported odds of preeclampsia among pregnant women who received COVID-19 vaccination during pregnancy.

The University of Oxford report describes data from 6,527 pregnant women across 18 countries enrolled between 2020 and 2022. Vaccination during pregnancy is presented as the key exposure in relation to hypertensive pregnancy outcomes within a pandemic-era, multinational cohort.

In comparisons between vaccinated and unvaccinated women and between groups with and without documented SARS-CoV-2 infection during pregnancy, with preeclampsia rates assessed across those strata, SARS-CoV-2 infection during pregnancy was associated with a 45% increased risk of preeclampsia, rising to 78% among unvaccinated women.

Receipt of a COVID-19 booster dose during pregnancy was associated with a statistically significant 33% reduction in the odds of preeclampsia, and the association remained after adjusting for key factors.